Untreated Chronic Lymphocytic Leukemia in Lebanese Patients: An Observational Study Using Standard Karyotyping and FISH

Figures & data

Table 1. Characteristics of the peripheral blood count of our watch and wait chronic lymphocytic leukemia patients.

Hemoglobin (g/dl)	Median	13.90
	Range	9.5–17.4
White blood cell count (/mm^3)	Median	17,600.00
	Range	2000–73,000
Neutrophil count (/mm^3)	Median	4540.00
	Range	330–16,060
Lymphocyte count (/mm^3)	Median	13,760.00
	Range	2080–54,020
Platelet count (/mm^3)	Median	209,000.00
	Range	123,000–338,000
NLR	Median	0.29
	Range	0.02–0.92
PLR	Median	15.20
	Range	2.3–190.7

NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio.

Table 2. The karyotype and FISH of our watch and wait chronic lymphocytic leukemia patients.

No.	Sex/age	ISCN cytogenetics	FISH
			TP53	ATM	c12	13q14	IGH	6q21/6q23
1	F/66	46,XX,del(11)(q14q23),del(13)(q13q22) (19)/46,XX (1)	N	D88.5%	N	D80%	D5’80.5%	N
2	M/55	46,XY,del(13)(q13q21) (8)/46,XY (12)	N	N	N	D63%	D5’83%	N
3	M/58	46,XY,del(13)(q13q21) (6)/46,XY (14)	N	N	N	D40.5%	N	N
4	F/71	46,XX (20)	N	N	N	N	D5’91.5%	N
5	M/68	46,XY (20)	N	N	N	D78.5%	N	N
6	F/73	46,XX (20)	N	N	N	N	N	N
7	M/51	46,XY,t(18;22)(q2?2;q1?2) (1)/46,idem,del(13)(q12q21) (17)/46,XY (2)	N	N	N	D85%	N	N
8	F/65	46,XX (20)	N	N	N	N	N	N
9	F/83	47,XX,+12 (18)/46,XX (2)	N	N	(+)63%	N	N	N
10	F/81	46,XX (20)	N	N	N	N	N	N
11	F/83	46,XX,inv(2)(p12q13) (15)/46,XX (5)	N	N	N	N	N	N
12	M/72	46,XY,del(11)(q1?3) (10)/46,XY (10)	N	D85%	N	D82.5%	N	N
13	M/71	46,Y,?t(X;13)(q2?6;q13) (4)/46,XY, t(11;15)(q2?5;q?21),del(13)(q12q22) (4)/46,XY,del(13)(q13q14) (3)/46,XY (19)	N	N	N	D35%	N	N
14	M/70	46,XY (20)	N	N	N	N	N	N
15	M/90	46,XY,dic(8;12)(p1?1;p1?1) (20)	N	N	(+)79.5%	N	N	N
16	M/60	46,XY (20)	N	N	N	N	N	N
17	F/61	46,XX,del(13)(q13q21), der(14)ins(?;14)(?;q?21) (10)/46,XX (10)	N	N	N	D84%	N	N
18	M/83	46,XY (20)	N	N	N	DD93.5%	N	N
19	M/41	46,XY,t(1;6)(p3?4;p2?5) (15)/46,XY (5)	N	N	N	N	D5’42.4%	N
20	M/40	44,XY,add(3)(q2?9),add(7)(q3?6),add(8)(p2?),-9,-11,tas(13;13)(q34:p13),-14,-15,-17,+4mar (7)/44,idem,del(10)(q2?2) (8)/46,XY (5)	D87.5%	N	N	D83.5%	S82%	N
21	M/70	45,XY,-13,der(18)t(13;18)(q21;q23) (17)/46,XY,add(13)(p13),-22-+mar (2)/46,XY (11)	N	N	N	D50.5%	N	N
22	M/44	46,XY (20)	D49.5%	N	N	N	S82%	N
23	F/62	46,XX (20)	N	N	N	DD70.5%	N	N
24	M/44	47,XY,+12 (18)/46,XX (2)	N	N	(+)78.5%	N	N	N
25	M/47	46,XY (20)	N	N	N	N	D5’36.5%	N
26	M/62	46,XY (20)	N	N	N	N	N	N
27	M/61	48,XY,+12,+mar (20)	N	N	(+)82.5%	DD82.5%	N	N
28	F/61	46,XX (20)	N	N	N	N	N	N

Separated signals; (+): three copies of CEP 12.

D: Monoallelic deletion; DD: Biallelic deletion; F: Female; ISCN: International System for Human Cytogenetic nomenclature; M: Male; N: Normal findings.